These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33652898)

  • 1. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario.
    Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S
    Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
    Berry SR; Hubay S; Soibelman H; Martin DK
    BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a novel prioritization framework on clinician-led oncology drug submissions.
    Keech J; Beca J; Eisen A; Kennedy E; Kim J; Kouroukis CT; Darling G; Ferguson SE; Finelli A; Petrella TM; Perry JR; Chan K; Gavura S
    Curr Oncol; 2019 Apr; 26(2):e155-e161. PubMed ID: 31043821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cross-sectional survey assessing the preparedness of the long-term care sector to respond to the COVID-19 pandemic in Ontario, Canada.
    Siu HY; Kristof L; Elston D; Hafid A; Mather F
    BMC Geriatr; 2020 Oct; 20(1):421. PubMed ID: 33092541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-19.
    Berlin A; Lovas M; Truong T; Melwani S; Liu J; Liu ZA; Badzynski A; Carpenter MB; Virtanen C; Morley L; Bhattacharyya O; Escaf M; Moody L; Goldfarb A; Brzozowski L; Cafazzo J; Chua MLK; Stewart AK; Krzyzanowska MK
    JAMA Oncol; 2021 Apr; 7(4):597-602. PubMed ID: 33410867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives.
    Loree JM; Dau H; Rebić N; Howren A; Gastonguay L; McTaggart-Cowan H; Gill S; Raghav K; De Vera MA
    Curr Oncol; 2021 Jan; 28(1):671-677. PubMed ID: 33499380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safeguarding cancer research funding by European charities amidst the COVID-19 pandemic.
    Tsagakis I; Papatriantafyllou M
    Mol Oncol; 2020 Dec; 14(12):2987-2993. PubMed ID: 33128324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 11. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
    Raymakers AJN; Regier DA; Peacock SJ
    Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective.
    de Joode K; Dumoulin DW; Engelen V; Bloemendal HJ; Verheij M; van Laarhoven HWM; Dingemans IH; Dingemans AC; van der Veldt AAM
    Eur J Cancer; 2020 Sep; 136():132-139. PubMed ID: 32683273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Cancer Care System Ill-Equipped to Deliver New Advances to Patients.
    Rappaport M
    J Oncol Pract; 2016 May; 12(5):397. PubMed ID: 27170686
    [No Abstract]   [Full Text] [Related]  

  • 15. How Australian Health Care Services Adapted to Telehealth During the COVID-19 Pandemic: A Survey of Telehealth Professionals.
    Taylor A; Caffery LJ; Gesesew HA; King A; Bassal AR; Ford K; Kealey J; Maeder A; McGuirk M; Parkes D; Ward PR
    Front Public Health; 2021; 9():648009. PubMed ID: 33718325
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient and clinician experience with a rapidly implemented large-scale video consultation program during COVID-19.
    Barkai G; Gadot M; Amir H; Menashe M; Shvimer-Rothschild L; Zimlichman E
    Int J Qual Health Care; 2021 Feb; 33(1):. PubMed ID: 33313891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
    Low E;
    J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
    [No Abstract]   [Full Text] [Related]  

  • 18. An urgent call to raise the bar in oncology.
    Schnog JB; Samson MJ; Gans ROB; Duits AJ
    Br J Cancer; 2021 Nov; 125(11):1477-1485. PubMed ID: 34400802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do oncologists believe new cancer drugs offer good value?
    Nadler E; Eckert B; Neumann PJ
    Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.